BC Week In Review | Jun 10, 2002
Company News

Chromagen, Sigma-Aldrich deal

The companies partnered to develop fluorescence-based assays for use in drug discovery. The deal combines Chromagen's fluorescence-based technologies with SIAL's reagent and marketing capabilities, and both companies will market resulting products. Also, SIAL received rights...
BC Extra | Mar 22, 2001
Financial News

Chromagen raises $15 million

Chromagen raised $15 million in private financing through Zesiger Capital; Essex Capital; S.A.C. Capital; DRW Venture Partners; United Capital; JAFCO; Nippon Venture Capital; and other investors. Chromagen (San Diego, Calif.) is developing assays and detection...
BC Week In Review | Apr 17, 2000
Company News

Chromagen, DuPont deal

The companies expanded for a second time their 1998 drug discovery agreement. Under the expansion, Chromagen will screen DuPont compound libraries using Chromagen's High Performance Single Amplification assays to identify new targets for DuPont's discovery...
BC Week In Review | Mar 20, 2000
Company News

Chromagen Inc, Merck deal

In an expansion of a 1998 agreement, Chromagen will develop and supply an increased number of gene expression and metabolic screening tests for MRK's drug discovery programs over a longer duration. Chromagen will use its...
BC Week In Review | Mar 22, 1999
Company News

Chromagen, CombiChem deal

Chromagen will develop biological assays and screen CCHM's compounds against multiple targets in CCHM's internal drug discovery program. Chromagen will receive research support and an undisclosed percentage of future payments received by CCHM upon licensing...
BC Week In Review | May 18, 1998
Company News

Chromagen, CombiChem deal

The companies will use CombiChem's Discovery Engine and Universal Informer Library to generate small molecules for screening in Chromagen's High Performance Amplification Assays to identify lead compound candidates. Chromagen will receive an upfront payment and...
BC Week In Review | Mar 9, 1998
Company News

Chromagen, CN Biosciences deal

CNBI will exclusively market and distribute worldwide Chromagen's Direct Read RNA and DNA assays and other products to the life sciences research products market. CNBI's Calbiochem-Novabiochem Corp. subsidiary (San Diego, Calif.) received exclusive access to...
BC Week In Review | Sep 2, 1997
Clinical News

Chromagen regulatory update

Chromagen received U.S. Patent No. 5,652,099 covering the discovery, composition and uses of highly fluorescent nucleotide analogs that allow direct labeling of DNA and RNA probes. The company also said it has received notice of...
BC Week In Review | Sep 2, 1997
Company News

Chromagen board of directors update

Chromagen Inc., San Diego, Calif.   Business: Diagnostics/Imaging   Appointed: President and CEO Michael Conrad, Ph.D., was appointed chairman; also named: Kenneth Cohen, president and CEO of Synbiotics Corp. ; Meyer Luskin, chairman, president and...
BC Week In Review | Nov 4, 1996
Clinical News

Chromagen regulatory update

Chromagen received notice of allowance for a U.S. patent covering a composition of matter for fluorescent nucleotide analogs and the uses of the analogs to create internally and end-labeled DNA and RNA probes for research,...
Items per page:
1 - 10 of 13
BC Week In Review | Jun 10, 2002
Company News

Chromagen, Sigma-Aldrich deal

The companies partnered to develop fluorescence-based assays for use in drug discovery. The deal combines Chromagen's fluorescence-based technologies with SIAL's reagent and marketing capabilities, and both companies will market resulting products. Also, SIAL received rights...
BC Extra | Mar 22, 2001
Financial News

Chromagen raises $15 million

Chromagen raised $15 million in private financing through Zesiger Capital; Essex Capital; S.A.C. Capital; DRW Venture Partners; United Capital; JAFCO; Nippon Venture Capital; and other investors. Chromagen (San Diego, Calif.) is developing assays and detection...
BC Week In Review | Apr 17, 2000
Company News

Chromagen, DuPont deal

The companies expanded for a second time their 1998 drug discovery agreement. Under the expansion, Chromagen will screen DuPont compound libraries using Chromagen's High Performance Single Amplification assays to identify new targets for DuPont's discovery...
BC Week In Review | Mar 20, 2000
Company News

Chromagen Inc, Merck deal

In an expansion of a 1998 agreement, Chromagen will develop and supply an increased number of gene expression and metabolic screening tests for MRK's drug discovery programs over a longer duration. Chromagen will use its...
BC Week In Review | Mar 22, 1999
Company News

Chromagen, CombiChem deal

Chromagen will develop biological assays and screen CCHM's compounds against multiple targets in CCHM's internal drug discovery program. Chromagen will receive research support and an undisclosed percentage of future payments received by CCHM upon licensing...
BC Week In Review | May 18, 1998
Company News

Chromagen, CombiChem deal

The companies will use CombiChem's Discovery Engine and Universal Informer Library to generate small molecules for screening in Chromagen's High Performance Amplification Assays to identify lead compound candidates. Chromagen will receive an upfront payment and...
BC Week In Review | Mar 9, 1998
Company News

Chromagen, CN Biosciences deal

CNBI will exclusively market and distribute worldwide Chromagen's Direct Read RNA and DNA assays and other products to the life sciences research products market. CNBI's Calbiochem-Novabiochem Corp. subsidiary (San Diego, Calif.) received exclusive access to...
BC Week In Review | Sep 2, 1997
Clinical News

Chromagen regulatory update

Chromagen received U.S. Patent No. 5,652,099 covering the discovery, composition and uses of highly fluorescent nucleotide analogs that allow direct labeling of DNA and RNA probes. The company also said it has received notice of...
BC Week In Review | Sep 2, 1997
Company News

Chromagen board of directors update

Chromagen Inc., San Diego, Calif.   Business: Diagnostics/Imaging   Appointed: President and CEO Michael Conrad, Ph.D., was appointed chairman; also named: Kenneth Cohen, president and CEO of Synbiotics Corp. ; Meyer Luskin, chairman, president and...
BC Week In Review | Nov 4, 1996
Clinical News

Chromagen regulatory update

Chromagen received notice of allowance for a U.S. patent covering a composition of matter for fluorescent nucleotide analogs and the uses of the analogs to create internally and end-labeled DNA and RNA probes for research,...
Items per page:
1 - 10 of 13